The Latest Cardiac and Vascular News
Innovative device prevents strokes – without medication – in at-risk heart patients SARASOTA, Fla., Feb. 6, 2025 /PRNewswire/ — Sarasota Memorial Hospital has earned the #1 spot among the world’s WATCHMAN providers protecting people with atrial fibrillation. This week, the Sarasota…
OKLAHOMA CITY, Feb. 5, 2025 /PRNewswire/ — Acarix, a pioneer in the development of groundbreaking acoustic-based cardiac diagnostic solutions, is proud to announce a new strategic partnership with Geo-Med, LLC, a renowned Service-Disabled Veteran-Owned Small Business that specializes in…
ST. LOUIS, Jan. 27, 2025 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received European CE Mark approval for the MAGiC™ ablation catheter. This approval is a significant milestone for Stereotaxis and for the community of physicians pioneering robotics in electrophysiology. It is reflective of the company’s commitment to advancing significant innovations that make robotics increasingly impactful across interventional medicine.
Secondary endpoints also showed a highly significant 67% reduction in major bleeding and an 89% reduction in gastrointestinal (GI) bleeding The company’s AZALEA-TIMI 71 study is the longest head-to-head study of a Factor XI inhibitor vs. a direct oral anticoagulant (DOAC) CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) — Anthos Therapeutics, Inc., a transformative, clinical-stage…
BOZEMAN, Mont., Jan. 22, 2025 /PRNewswire/ — Atrial fibrillation (AF) is the most common abnormal heart rhythm affecting 6 million people in the USA and can cause strokes and heart failure. Conventional treatments are successful but may need to be repeated, have inherent risks, and are…
MIAMI–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the late-breaking data from its Nanosecond PFA 360° Cardiac Catheter System first-in-human feasibility study, which data were recently presented at the 30th Annual AF Symposium 2025 meeting. “This novel technology […]
JANUARY 17, 2025 – Medtronic, a global leader in healthcare technology, today announced new data and case presentations for the company’s pulsed field ablation (PFA) technologies, Affera™ Mapping and Ablation System with Sphere-9™ Catheter and PulseSelect™, to be presented at the AF Symposium in Boston, MA. “We are encouraged by the […]
Expanded relationship includes joint research studies to test the feasibility of a combined electrocardiogram and magnetocardiogram approach using SandboxAQ’s Quantitative AI to integrate and interpret the results PALO ALTO, Calif., Jan. 17, 2025 /PRNewswire/ — SandboxAQ, a leader in…
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Ablation System Sub-analysis from OPTION clinical trial highlights consistent safety and…
Abstract presentation will feature the first clinical use of the company’s CLAAS® AcuFORM™ Left Atrial Appendage Occlusion (LAAO) Device NASHUA, N.H., Jan. 16, 2025 /PRNewswire/ — Conformal Medical, Inc., today announced that the early results of its GLACE Study will be presented during…
